716362-10-6

Basic information

• Product Name: 6-Chloro-4-methoxynicotinic acid
• Synonyms: 3-Pyridinecarboxylic acid, 6-chloro-4-Methoxy-;6-Chloro-4-methoxy-3-pyridinecarboxylic acid;6-Chloro-4-methoxynicotinic acid;6-chloro-4-Methoxypyridine-3-carboxylic acid
• CAS NO: 716362-10-6
• Molecular Formula: C₇H₆ClNO₃
• Molecular Weight: 187.58
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 716362-10-6.mol

Chemical Properties

• Appearance: /
• Density: 1.430
• Refractive Index: 1.567
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-Chloro-4-methoxynicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-4-methoxynicotinic acid(716362-10-6)
• EPA Substance Registry System: 6-Chloro-4-methoxynicotinic acid(716362-10-6)

Safety Data

• Safety Statements: 24/25
• HazardClass: IRRITANT
• Hazardous Substances Data: 716362-10-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-4-methoxynicotinic acid is used as a key intermediate for the preparation of benzimidazolylazabicyclooctylethylpiperidines. These compounds serve as Ccr5 antagonists, which play a crucial role in the treatment of HIV infection. By targeting the Ccr5 receptor, these antagonists can inhibit the entry of the HIV virus into host cells, thus helping to control the progression of the disease.

InChI:InChI=1/C7H6ClNO3/c1-12-5-2-6(8)9-3-4(5)7(10)11/h2-3H,1H3,(H,10,11)

Upstream product

• 67-56-1 methanol 
• 73027-79-9 4,6-dichloro-nicotinic acid 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 
• 84332-02-5 methyl 6-chloro-4-methoxypyridine-3-carboxylate 
• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 

Downstream Products

• 1609528-26-8 C₁₈H₁₆FN₅O 
• 1609528-73-5 C₁₈H₁₇FN₆O 
• 1609529-22-7 C₁₉H₁₉FN₆O₃S 

Relevant articles and documents

PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORgT

The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

2-ALKOXY-6-[18F]FLUORONICOTINOYL SUBSTITUTED LYS-C(O)-GLU DERIVATIVES AS EFFICIENT PROBES FOR IMAGING OF PSMA EXPRESSING TISSUES

6-[18HF]Fluoro-2-alkoxynicotinoyl substituted Lys-C(O)-Glu derivatives were identified as efficient imaging probes for PSMA expressing tissues in comparison to other known PSMA specific ligands like [18F]DCFPyL, [68Ga]HBED-CC-PSMA, [

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES

The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to methods of using these compounds for the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

Structure-based design of substituted piperidines as a new class of highly efficacious oral direct renin inhibitors

A cis-configured 3,5-disubstituted piperidine direct renin inhibitor, (syn,rac)-1, was discovered as a high-throughput screening hit from a target-family tailored library. Optimization of both the prime and the nonprime site residues flanking the central piperidine transition-state surrogate resulted in analogues with improved potency and pharmacokinetic (PK) properties, culminating in the identification of the 4-hydroxy-3,5-substituted piperidine 31. This compound showed high in vitro potency toward human renin with excellent off-target selectivity, 60% oral bioavailability in rat, and dose-dependent blood pressure lowering effects in the double-transgenic rat model.

ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES

Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I)

ORGANIC COMPOUNDS

The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.